ProC6C-AlOH/Matrix-M疫苗抗恶性疟原虫感染及蚊媒传播的2期随机对照人疟感染研究
在疟疾高暴露的非洲成人中开展随机双盲对照人疟感染(CHMI)试验,评估多阶段疟疾疫苗ProC6C-AlOH/MM(100 μg ProC6C+50 μg Matrix-M)与狂犬病疫苗对照的效力。接种组不良事件更常见但多为轻度。
要点
- ProC6C-AlOH/MM在末次接种后12周对CHMI的疫苗效力为76%(95%CI 36-91)。
- 接种组不良事件报告率76%(13/17)高于对照组18%(3/17),几乎均为轻度。
核心结论
- ProC6C-AlOH/MM是首个在末次接种12周后对CHMI显示出超过50%疫苗效力的抗PfCSP亚单位疫苗。
- 该疫苗效力与一种新型、强且机制合理的保护相关物有关。
研究设计与样本
- 在非洲马里Sotuba开展随机对照双盲疫苗接种及CHMI研究,受试者为18-50岁有终身疟疾暴露的健康成人。
- 受试者按1:1随机接受三剂ProC6C-AlOH/MM(100 μg ProC6C和50 μg Matrix-M佐剂)或Verorab狂犬病疫苗(对照),间隔4周肌肉注射。
- 末次接种94天后,仍参与研究的受试者经皮内接种22 500个恶性疟原虫子孢子(Sanaria PfSPZ Challenge [NF54])进行CHMI。
主要发现
- 2024年3月20日、4月15日和5月9日共34人接种(ProC6C-AlOH/MM组17人,对照组17人;15男19女)。
- 接种耐受良好,ProC6C-AlOH/MM组17人中13人(76%)发生至少1起不良事件(几乎均为轻度),对照组17人中3人(18%)。
- 末次接种94天后32人接受CHMI,至CHMI后第28天19人(59%)出现恶性疟原虫血症(对照组16人中13人,ProC6C-AlOH/MM组16人中6人)。
临床怎么用
- 后续需按年龄递减开展2期研究,在学龄前和小学龄儿童中评估ProC6C对自然获得性临床疟疾和传播的疫苗效力。
局限性
- 研究仅纳入有终身疟疾暴露的非洲成人,结果不能直接外推至儿童或低暴露人群。
- CHMI使用单一恶性疟原虫株(NF54),不能完全反映自然感染多株攻击的保护效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An investigational multistage malaria vaccine, ProC6C, based on distinct Plasmodium falciparum epitopes from the sporozoite stage (P falciparum circumsporozoite protein [PfCSP]) and the transmission stages (Pfs230 and Pfs48/45), adsorbed to aluminium hydroxide (AlOH) and adjuvanted with Matrix-M adjuvant (ProC6C-AlOH/MM), has previously shown safety and immunogenicity in phase 1 studies. We aimed to study vaccine efficacy, safety, and immunogenicity in African adults with lifelong malaria exposure. METHODS: This randomised controlled double-blind vaccination and controlled human malaria infection (CHMI) study was conducted in Sotuba, a peri-urban setting in Mali. Healthy adults (aged 18-50 years), who were malaria experienced and met eligibility criteria, were randomly assigned (1:1) to receive three intramuscular injections of ProC6C-AlOH/MM (100 μg ProC6C and 50 μg Matrix-M adjuvant) or Verorab rabies vaccine (control) 4 weeks apart. Randomisation was done in randomly permuted blocks (random varying block size of two and four) using R Statistical Software (randomizr and blockrand). The content of syringes was masked to ensure blinding and only those responsible for vaccine preparation were unblinded. 94 days after the last vaccination, all participants still in the study underwent CHMI by intradermal inoculation of 22 500 P falciparum sporozoites (Sanaria PfSPZ Challenge [NF54]). Primary outcomes were time to blood-stage infection (quantitative PCR detection of P falciparum, with vaccine efficacy defined as 1 - Cox hazard ratio in the per-protocol population) and vaccine safety and tolerability (in those who were randomly assigned and received at least one vaccination). The trial was registered in the Pan African Clinical Trial Registry (PACTR202404598604620). FINDINGS: On March 20, April 15, and May 9, 2024, 34 participants (15 males, 19 females) received their vaccinations (n=17 ProC6C-AlOH/MM and n=17 control vaccine). The vaccinations were well tolerated, with 13 (76%) of 17 ProC6C-AlOH/MM recipients experiencing at least one adverse event, almost all of which were mild, compared with three (18%) of 17 control vaccine recipients. On Aug 11, 2024, 94 days after the last dose of vaccine, 32 of 34 participants underwent CHMI, of whom 19 (59%) developed P falciparum parasitaemia by day 28 post-CHMI initiation (13 of 16 in the control group and six of 16 in the ProC6C-AlOH/MM group). In those that became parasitaemic, the median time to positivity was delayed in ProC6C-AlOH/MM recipients by 2 days (14 days ProC6C-AlOH/MM, 12 days control; p=0·049). In the per-protocol time-to-event analysis, vaccine efficacy was 76% (95% CI 36-91, p=0·0022). By proportional analysis (1 - risk ratio) the vaccine efficacy was 54% (95% CI 9-77, p=0·029). INTERPRETATION: This is the first clinical trial of an anti-PfCSP subunit vaccine that has shown greater than 50% vaccine efficacy against CHMI at 12 weeks after the last vaccine dose, associated with a novel, strong, and mechanistically plausible correlate of protection. Following age de-escalation, future phase 2 studies with ProC6C should therefore assess vaccine efficacy against naturally acquired clinical malaria and onward transmission in the target population, preschool-aged and primary-school-aged children. FUNDING: European & Developing Countries Clinical Trials Partnership (EDCTP2 programme) and Gates Foundation. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Kone M, Plieskatt J, Thienta M, et al. Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study. Lancet Infect Dis. 2025. PMID: 41418800. doi:10.1016/S1473-3099(25)00664-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。